RADIATION THERAPY ONCOLOGY GROUP
RTOG 0521
A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND 3DCRT/IMRT VS. AS AND 3DCRT/IMRT FOLLOWED BY CHEMOTHERAPY WITH DOCETAXEL AND PREDNISONE FOR LOCALIZED, HIGH-RISK PROSTATE CANCER
Protocol Participation Information
RTOG 0521
A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND 3DCRT/IMRT VS. AS AND 3DCRT/IMRT FOLLOWED BY CHEMOTHERAPY WITH DOCETAXEL AND PREDNISONE FOR LOCALIZED, HIGH-RISK PROSTATE CANCER
Please note: RTOG 0521 is closed to accrual as of August 21, 2009.
- Credentialing
- Credentialing Requirements
- Facility Questionnaire: Part I is required for this protocol.
- How to Participate
- Digital Data Submission Procedures
- Digital Data Submission Information (DDSI) Form
- Data Submission Check list
- ATC Compliant Treatment Planning Systems
- Structure Names
- Pelvic Nodal Atlas (RT)
- Contouring Examples (from RTOG 0126)
- Protocol Text (http://www.rtog.org/)
Back to protocols
